Click here for Vyndaqel®▼ (tafamidis) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, under-recognised, and underdiagnosed condition that mostly affects older adults1, there could be one patient in every heart failure clinic2.
Navigate the site to increase your understanding of the causes of the disease, signs and symptoms, diagnostic tools, and current and emerging treatment strategies, which can help to reduce the delay in the diagnosis and subsequent treatment of this ultimately fatal disease.
You can also visit the Educational Resources section to sign up to a virtual event or watch an expert speaker video.
Understand ATTR-CM and why it is underdiagnosed
Uncover the differences between hereditary and wild-type ATTR-CM
Learn about techniques used to diagnose ATTR-CM, such as endomyocardial biopsy and nuclear scintigraphy
Learn about current and emerging therapies for ATTR-CM
Discover emerging therapies
Explore educational resources surrounding ATTR-CM
Explore educational resources
An easier way to connect with a member of the Pfizer team
1. Witteles RM, Bokhari S, Damy T et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019; 7(8): 709–716
2. Pfizer Data on File PP-VYN-GBR-0145 2020
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020